Literature DB >> 20503276

Motor performance is better than normal in preschool children with cystic fibrosis.

Wolfgang Gruber1, David M Orenstein, Karl Paul, Gerd Hüls, Klaus M Braumann.   

Abstract

The aim of the present study was to assess the motor performance in preschool children with a reliable and valid test battery developed to identify motor dysfunction and normal motor development in children aged from 4 to 6 years. Several aspects of motor performance were examined in 29 preschool children with cystic fibrosis (CF) age range 4-6 years (mean 5.2 +/- 0.8 years), FEV(1) 97.2 +/- 15.3pred and compared to with 22 healthy children of the same age 5.5 +/- 0.8 years. All children performed the "Motoriktest fuer 4-6jaehrige Kinder" (MOT) assessing seven different aspects of motor performance. Compared to healthy children, test score "Motor Quotient" (MQ) as the mean of all test items was significantly higher (P < 0.05) in children with CF (108.1 +/- 16 vs. 93.5 +/- 17.9). In both groups, the MQ can be classified as normal. Children with CF scored higher in MOT subtests "Agility and Coordination" (P < 0.05) and "Balance" (P < 0.01) than healthy children but not in the other subtests. We speculate that chest physiotherapy in preschool children with CF may have an effect on motor performance in general and in some aspects of motor performance.

Entities:  

Mesh:

Year:  2010        PMID: 20503276     DOI: 10.1002/ppul.21098

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  2 in total

1.  Fundamental movement skill proficiency and objectively measured physical activity in children with bronchiectasis: a cross-sectional study.

Authors:  Barbara Joschtel; Sjaan R Gomersall; Sean Tweedy; Helen Petsky; Anne B Chang; Stewart G Trost
Journal:  BMC Pulm Med       Date:  2021-08-17       Impact factor: 3.317

2.  Motor repertoire is age-inadequate in infants with cystic fibrosis.

Authors:  Haluk Tekerlek; Akmer Mutlu; Deniz Inal-Ince; Ayse Livanelioglu; Aysu Kahraman; Sanem Eryilmaz-Polat; Jale Karakaya; Ugur Ozcelik
Journal:  Pediatr Res       Date:  2020-07-27       Impact factor: 3.756

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.